StockData
AC Immune SA logo

AC Immune SA (ACIU) company profile

ACIUNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Mar 13, 2026Score 3/30
$2.11+0.02 (+0.96%)

Close on Nov 17, 2026Market cap $214.68MP/E –Yield –

About AC Immune

Pharmaceutical Preparations, SIC 2834

AC Immune SA is a clinical-stage biopharmaceutical company that discovers and develops precision therapeutics and diagnostic agents for neurodegenerative disorders, particularly Alzheimer’s disease and Parkinson’s disease. The company's pipeline comprises active immunotherapies, brain-penetrant small molecule inhibitors, monoclonal antibodies, and diagnostic positron emission tomography imaging tracers. These investigational candidates target misfolded pathological proteins, including amyloid beta, tau, alpha-synuclein, and TDP-43. AC Immune operates primarily through research, development, and licensing arrangements with major global pharmaceutical companies, which serve as commercialization partners alongside clinical trial participants.

The company is headquartered in Ecublens at the EPFL Innovation Park in Lausanne, Switzerland. Its operations and clinical research activities extend internationally, with clinical trials conducted across Europe and North America, including sites in the United States, the United Kingdom, the Netherlands, and Spain. AC Immune collaborates with multinational healthcare corporations across global markets to advance its therapeutic and diagnostic pipelines.

Summary of the business section of AC Immune's latest annual report, written by StockData.

Company profile

Company

Legal name
AC Immune SA
Founded
2003
Headquarters
1015 Lausanne, V8
Address
Epfl Innovation Park, Building B 00000
Phone
41 21 345 91 21
Employees
122, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
V8
Fiscal year ends
December 31
Auditor
PricewaterhouseCoopers SA, Lausanne, Switzerland

Stock & identifiers

Ticker
ACIU
Exchange
Nasdaq
IPO date
Sep 23, 2016
Shares outstanding
102M, Dec 31, 2025
Filer category
Accelerated filer
SEC CIK
1651625
FIGI
BBG00D0RHJ38
Share class FIGI
BBG00D0RHJ65
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Martin ZuegelInterim CEO, Director71,408
Andrea PfeiferChief Executive Officer, Director3,834,288
Piergiorgio DonatiChief Operating Officer141,120
Christopher James RobertsChief Financial Officer155,382
Thomas GraneyDirector12,959
Roy Ervin TwymanDirector92,556
Monika BuetlerDirector71,656
Carl Howard JuneDirector67,556
Renee Aguiar-LucanderDirector51,136

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Sep 23, 2016
Offer price
$11.00
Securities offered
6,000,000
Gross proceeds
$66.00M
Exchange
Nasdaq
First trading day
Sep 23, 2016
First-day close
$15.66+42.4%
Lock-up ends (est.)
Mar 22, 2017

“The initial public offering price is $11.00 per common share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we employed 122 employees, 32 of whom were part-time employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?